HNF4G and FOXA1 are context-specific drivers of pancreatic cancer progression [RNA-seq]
RNA-seq (gene expression) · human · 29 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 29 samples: 29 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Transcription factor switching drives subtype-specific pancreatic cancerNature genetics · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE245733_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1029636 and SRA study SRP467179. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 29 sample titles: 29 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7847594 jc8244_HPAFII_Cas_9_EV
- GSM7847595 jc8245_HPAFII_Cas_9_EV
- GSM7847596 jc8247_HPAFII_Cas_9_EV
- GSM7847597 jc8248_HPAFII_HNF4G_knockout_EV
- GSM7847598 jc8249_HPAFII_HNF4G_knockout_EV
- GSM7847599 jc8250_HPAFII_HNF4G_knockout_EV
- GSM7847600 jc8251_HPAFII_HNF4G_knockout_EV
- GSM7847601 jc8252_HPAFII_HNF4G_knockout_EV
- GSM7847602 jc8253_HPAFII_HNF4G_knockout_EV
- GSM7847603 jc8254_HPAFII_Cas_9_FOXA1
- GSM7847604 jc8255_HPAFII_Cas_9_FOXA1
- GSM7847605 jc8256_HPAFII_Cas_9_FOXA1
- GSM7847606 jc8257_HPAFII_HNF4G_knockout_FOXA1
- GSM7847607 jc8258_HPAFII_HNF4G_knockout_FOXA1
- GSM7847608 jc8259_HPAFII_HNF4G_knockout_FOXA1
- GSM7847609 jc8260_HPAFII_HNF4G_knockout_FOXA1
- GSM7847610 jc8261_HPAFII_HNF4G_knockout_FOXA1
- GSM7847611 jc8262_HPAFII_HNF4G_knockout_FOXA1
- GSM7847612 jc8263_HPAFII_HNF4G_knockout_FOXA1
- GSM7847613 jc8264_HPAFII_HNF4G_knockout_FOXA1
- GSM7847614 jc8265_HPAFII_HNF4G_knockout_FOXA1
- GSM7847615 jc8523_kpc_tumour
- GSM7847616 jc8524_kpc_liver_mets
- GSM7847617 jc8525_kpc_tumour
- GSM7847618 jc8526_kpc_liver_mets
- GSM7847619 jc8527_kpc_tumour
- GSM7847620 jc8528_kpc_liver_mets
- GSM7847621 jc8529_kpc_tumour
- GSM7847622 jc8530_kpc_liver_mets
- GSE245734 HNF4G and FOXA1 are context-specific drivers of pancreatic cancer progression 225 samples shares hnf4g, foxa1, context-specific, progression, pancreatic, drivers
- GSE245731 HNF4G and FOXA1 are context-specific drivers of pancreatic cancer progression [ChIP-seq] 172 samples shares hnf4g, foxa1, context-specific, progression, pancreatic, drivers
- GSE260725 Individual RNA-seq for different prostate cancer cells and Lucap35CR PDX treated by SR8278,JQ1,AZD5153,ENZ or by FOXA1 and NR1D1 gene knockdown or NR1D1 overexpression. 26 samples shares foxa1, rna-seq
- GSE278785 Obesity facilitated colon cancer progression is mediated by increased diacylglycerol o-acyltransferases 1 and 2 (DGAT1/2) levels [RNA-seq] 26 samples shares progression, rna-seq
- GSE99284 Enhancer reprogramming promotes pancreatic cancer progression and metastasis [ChIP-seq] 90 samples shares progression, pancreatic
- GSE298580 Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D 64 samples shares progression, pancreatic
- GSE282726 FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment 25 samples shares foxa1
- GSE333317 Adrenal-derived factors drive progression of sclerotic prostate cancer in bone 48 samples shares progression
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.